Ns EOC: Epithelial ovarian cancer; RT-qPCR: Reverse transcriptase quantitative polymerase chain

Ns EOC: Epithelial ovarian cancer; RT-qPCR: Reverse transcriptase quantitative polymerase chain reaction; OS: General survival; SELDI: Surface-enhanced laser desorption/ionization; RCA: Rolling circle amplification; LMP: Low malignant potential, OVCAD, OVarian CAncer: Diagnosis of a silent killer; EDTA: Ethylenediaminetetraacetic acid; USC: Uncorrelated shrunken centroids; ANOVA: Analysis of variance; SAM: Significance evaluation of microarrays; ROC: Receiver operating characteristic; AUC: Location under the ROC curve; CI: Self-confidence interval; FIGO: International Federation of Gynecology and Obstetrics; FC: Fold alter. Competing interests A patent was filed (DP, DT, RZ). Authors’ contributions DP, DT, and RZ concepted and made the study. DP, GH, ESch, and AW performed microarray and RT-qPCR experiments. EO performed the multiplexed immunoassays. DP made the microarray bioinformatics and DP, GH, and MK analyzed the data statistically. SA, JS, IB, IV, TVG, SM, NC, and PS recruited sufferers, collected patient samples and data, and revised the manuscript critically. DP, SA and RZ wrote the manuscript and all authors study and approved the final manuscript. Acknowledgements This work was supported by the Sixth Framework Programme (FP6) Project of the European Union (EU) called “Ovarian Cancer: Diagnosis of a silent killer OVCAD”, no. 018698, the Austrian Science Fund (FWF) project, no. I 1216-B19, and the Ludwig Boltzmann Cluster “Translational Oncology”.DiBAC4 Epigenetics We thank Ingrid Schiebl for her great technical assistance. Author specifics Division of Obstetrics and Gynecology, Molecular Oncology Group, Healthcare University of Vienna, European Union, Vienna, Austria. 2Ludwig Boltzmann Cluster “Translational Oncology”, General Hospital Vienna, European Union, Waehringer Guertel 18-20, Room-No.: five.Q9.27, A-1090, Vienna, Austria. 3Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Health-related University of Vienna, European Union, Vienna, Austria. 4Department of Gynecology, Campus Virchow Klinikum, Charite Medical University, European Union, Berlin, Germany. 5 Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospitals Leuven, Katholieke Universiteit Leuven, European Union, Leuven, Belgium.Zinc Protoporphyrin Reactive Oxygen Species 6Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, MUMC+, Grow School for Oncology and Developmental Biology, European Union, Maastricht, The Netherlands.PMID:23551549 7Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, European Union, Hamburg, Germany. 8Department of Gynecology and Obstetrics, Innsbruck Healthcare University, European Union, Innsbruck, Austria.Received: 25 July 2012 Accepted: 18 March 2013 Published: three AprilPils et al. BMC Cancer 2013, 13:178 http://www.biomedcentral/1471-2407/13/Page 13 ofReferences 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):22549. two. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma from the ovary. FIGO 26th annual report on the final results of remedy in gynecological cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161 192. three. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68(5):1331337. four. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ov.